Scoop: Corporate development chief hits the exit at Biogen as aducanumab jitters roll on
Michel Vounatsos has lost another member of his executive team.
Less than 2 years after Daniel Karp was hired on as the EVP of corporate development — where he ran the strategy and BD teams — he’s now hitting the exit as the company finds itself at a momentous crossroads.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.